Amy C. Shurtleff

3.6k total citations
30 papers, 1.4k citations indexed

About

Amy C. Shurtleff is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Amy C. Shurtleff has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 8 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Amy C. Shurtleff's work include Viral Infections and Outbreaks Research (23 papers), Viral Infections and Vectors (19 papers) and Viral gastroenteritis research and epidemiology (8 papers). Amy C. Shurtleff is often cited by papers focused on Viral Infections and Outbreaks Research (23 papers), Viral Infections and Vectors (19 papers) and Viral gastroenteritis research and epidemiology (8 papers). Amy C. Shurtleff collaborates with scholars based in United States, Canada and France. Amy C. Shurtleff's co-authors include Sina Bavari, Travis K. Warren, Mary C. Guttieri, Andrey A. Kolokoltsov, Robert A. Davey, Rekha G. Panchal, Peter B. Madrid, Carol E. Green, Ian D. Manger and Mary J. Tanga and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

Amy C. Shurtleff

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy C. Shurtleff United States 19 1.0k 338 291 229 108 30 1.4k
Lisa Oestereich Germany 22 1.3k 1.2× 405 1.2× 328 1.1× 135 0.6× 90 0.8× 47 1.5k
Cary Retterer United States 16 863 0.8× 359 1.1× 182 0.6× 224 1.0× 146 1.4× 24 1.3k
Sean M. Amberg United States 17 1.1k 1.1× 304 0.9× 584 2.0× 214 0.9× 109 1.0× 22 1.6k
Tina Thomas United States 18 1.1k 1.1× 230 0.7× 195 0.7× 182 0.8× 149 1.4× 25 1.5k
Kie‐Hoon Jung United States 16 686 0.7× 244 0.7× 187 0.6× 118 0.5× 209 1.9× 21 1.0k
Pamela J. Glass United States 22 1.3k 1.2× 326 1.0× 526 1.8× 312 1.4× 158 1.5× 47 1.7k
Elena Postnikova United States 22 691 0.7× 252 0.7× 79 0.3× 232 1.0× 82 0.8× 47 1.7k
Viktoriya Borisevich United States 28 1.7k 1.7× 1.1k 3.2× 286 1.0× 298 1.3× 140 1.3× 76 2.2k
Travis K. Warren United States 28 2.0k 2.0× 843 2.5× 308 1.1× 514 2.2× 242 2.2× 54 2.9k
Charles J. Shoemaker United States 17 1.1k 1.0× 328 1.0× 286 1.0× 219 1.0× 124 1.1× 33 1.4k

Countries citing papers authored by Amy C. Shurtleff

Since Specialization
Citations

This map shows the geographic impact of Amy C. Shurtleff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy C. Shurtleff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy C. Shurtleff more than expected).

Fields of papers citing papers by Amy C. Shurtleff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy C. Shurtleff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy C. Shurtleff. The network helps show where Amy C. Shurtleff may publish in the future.

Co-authorship network of co-authors of Amy C. Shurtleff

This figure shows the co-authorship network connecting the top 25 collaborators of Amy C. Shurtleff. A scholar is included among the top collaborators of Amy C. Shurtleff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy C. Shurtleff. Amy C. Shurtleff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bixler, Sandra L., Amy C. Shurtleff, Kenneth Liu, et al.. (2025). Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model. Viruses. 17(3). 342–342.
2.
Yimer, Solomon Abebe, Maïna L’Azou, Richard G. Jarman, et al.. (2024). Rapid diagnostic test: a critical need for outbreak preparedness and response for high priority pathogens. BMJ Global Health. 9(4). e014386–e014386. 15 indexed citations
3.
Gunn, Bronwyn M., Ryan P. McNamara, Wenyu Guo, et al.. (2023). Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. Cell Reports. 42(4). 112402–112402. 12 indexed citations
4.
Konduru, Krishnamurthy, Amy C. Shurtleff, Sina Bavari, & Gerardo Kaplan. (2018). High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test. Journal of Virological Methods. 254. 1–7. 19 indexed citations
5.
Warfield, Kelly L., Travis K. Warren, Xiangguo Qiu, et al.. (2016). Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Research. 138. 22–31. 20 indexed citations
6.
Konduru, Krishnamurthy, et al.. (2016). Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS ONE. 11(9). e0162446–e0162446. 23 indexed citations
7.
Shurtleff, Amy C., Chris A. Whitehouse, Michael D. Ward, Lisa H. Cazares, & Sina Bavari. (2015). Pre-symptomatic diagnosis and treatment of filovirus diseases. Frontiers in Microbiology. 6. 108–108. 13 indexed citations
8.
Shurtleff, Amy C. & Sina Bavari. (2015). Animal models for ebolavirus countermeasures discovery: what defines a useful model?. Expert Opinion on Drug Discovery. 10(7). 685–702. 28 indexed citations
9.
Martins, Karen, John H. Carra, Christopher L. Cooper, et al.. (2014). Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. Viral Immunology. 28(1). 62–70. 18 indexed citations
10.
Reid, St. Patrick, Amy C. Shurtleff, Sarah R. Tritsch, et al.. (2014). HSPA5 is an essential host factor for Ebola virus infection. Antiviral Research. 109. 171–174. 83 indexed citations
11.
Page, Audrey, Valentina A. Volchkova, Mathieu Mateo, et al.. (2014). Marburgvirus Hijacks Nrf2-Dependent Pathway by Targeting Nrf2-Negative Regulator Keap1. Cell Reports. 6(6). 1026–1036. 73 indexed citations
12.
Madrid, Peter B., Sidharth Chopra, Ian D. Manger, et al.. (2013). A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. PLoS ONE. 8(4). e60579–e60579. 188 indexed citations
13.
Konduru, Krishnamurthy, Amy C. Shurtleff, Sina Bavari, & Gerardo Kaplan. (2013). Evaluation of ebolavirus glycoprotein Fc fusion protein as a subunit vaccine (P4417). The Journal of Immunology. 190(Supplement_1). 205.18–205.18. 4 indexed citations
14.
Warren, Travis K., Amy C. Shurtleff, & Sina Bavari. (2012). Advanced morpholino oligomers: A novel approach to antiviral therapy. Antiviral Research. 94(1). 80–88. 46 indexed citations
15.
Shurtleff, Amy C., et al.. (2012). Therapeutics for filovirus infection: traditional approaches and progress towardsin silicodrug design. Expert Opinion on Drug Discovery. 7(10). 935–954. 13 indexed citations
16.
Bradfute, Steven B., Kelly S. Stuthman, Amy C. Shurtleff, & Sina Bavari. (2011). A STAT-1 knockout mouse model for Machupo virus pathogenesis. Virology Journal. 8(1). 300–300. 37 indexed citations
17.
Geisbert, Thomas W., Steven J.M. Jones, Elizabeth A. Fritz, et al.. (2005). Development of a New Vaccine for the Prevention of Lassa Fever. PLoS Medicine. 2(6). e183–e183. 188 indexed citations
18.
Spik, Kristin, Amy C. Shurtleff, Anita K. McElroy, et al.. (2005). Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine. 24(21). 4657–4666. 117 indexed citations
19.
Shurtleff, Amy C.. (2004). Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.. PubMed. 7(2). 91–5. 2 indexed citations
20.
Shurtleff, Amy C., David W.C. Beasley, Haolin Ni, et al.. (2001). Genetic Variation in the 3′ Non-Coding Region of Dengue Viruses. Virology. 281(1). 75–87. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Oestereich Breakdown of academic impact, for papers by Cary Retterer Breakdown of academic impact, for papers by Sean M. Amberg Breakdown of academic impact, for papers by Tina Thomas Breakdown of academic impact, for papers by Kie‐Hoon Jung Breakdown of academic impact, for papers by Pamela J. Glass Breakdown of academic impact, for papers by Elena Postnikova Breakdown of academic impact, for papers by Viktoriya Borisevich Breakdown of academic impact, for papers by Travis K. Warren Breakdown of academic impact, for papers by Charles J. Shoemaker
Rankless by CCL
2026